ApoA-I Data Presented at European Society of Cardiology Congress
Calgary, Canada (ots/PRNewswire)
- Multiple Presentations Included Resverlogix Data
- TSX Exchange Symbol: RVX
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is
pleased to announce that Dr. Norman Wong presented key clinical data
pertaining to its lead compound, RVX-208, at the European Society
Cardiology (ESC) 2008 Congress in Munich. The presentation titled
"RVX-208 a novel small molecule that increases apolipoprotein A-I
enters into human clinical trials" was delivered on August 31, 2008.
In addition to this presentation, other important data relating to
RVX-208 from Resverlogix's extensive data portfolio was presented by
Dr. Jacques Genest of McGill University and Dr. Stephen Nicholls of
the Cleveland Clinic, at the same conference."Over the past year, the scientific community has pushed to the forefront the importance of a small molecule in the form of an oral tablet that significantly increases ApoA-I production, HDL functionality and thereby treats atherosclerosis cardiovascular disease," stated Dr. Jan Johansson, Senior Vice President Medical Affairs Resverlogix. Johansson further added, "The ESC is a well regarded scientific meeting as well as one of the largest with an estimated 25,000 participants. We are pleased to have presented our data to this esteemed audience."
Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for elimination from the body. In multiple human and animal studies over- expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in animals and humans.
RVX-208, a novel small molecule drug that facilitates endogenous ApoA-I production, is positioned as an emerging drug that holds the most promise for the treatment of atherosclerosis. RVX-208 is designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF- Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email: Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email: Sarah@resverlogix.com
Website: http://www.resverlogix.com
Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor
Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email:
Sarah@resverlogix.com